Our findings revealed that ITGB2 is positively correlated with 16 TME features associated with immunotherapy response, suggesting that ITGB2 may be a viable marker for assessing the immunotherapy response in ESCC patients. Here, ITGB2 is linked to esophageal squamous cell carcinoma.